310 related articles for article (PubMed ID: 26050241)
1. Severe opioid withdrawal syndrome after a single dose of nalmefene.
Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
[No Abstract] [Full Text] [Related]
2. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
[No Abstract] [Full Text] [Related]
3. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
[TBL] [Abstract][Full Text] [Related]
4. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
Franchitto N; Jullian B; Salles J; Pelissier F; Rolland B
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):669-677. PubMed ID: 28343423
[TBL] [Abstract][Full Text] [Related]
5. Opioid-dependent error processing.
Fellows-Smith J
J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
Diot C; Eiden C; Roussin A; Batisse A; Boucher A; Chavant F; Daveluy A; Donadieu-Rigole H; Peyrière H;
Eur J Clin Pharmacol; 2015 Dec; 71(12):1539-40. PubMed ID: 26329380
[No Abstract] [Full Text] [Related]
7. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Dahmke H; Kupferschmidt H; Kullak-Ublick GA; Weiler S
Praxis (Bern 1994); 2015 Oct; 104(21):1129-34. PubMed ID: 26463904
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
9. The diverse clinical uses of opioid receptor drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
Lescut C; Gaboriau L; Carton L; Rolland B
J Clin Psychopharmacol; 2017 Oct; 37(5):631-633. PubMed ID: 28806388
[No Abstract] [Full Text] [Related]
11. Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
Cheskin LJ; Chami TN; Johnson RE; Jaffe JH
Drug Alcohol Depend; 1995 Aug; 39(2):151-4. PubMed ID: 8529534
[TBL] [Abstract][Full Text] [Related]
12. Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.
Green A; Kaul A; O'Shea J; Sharma E; Bennett L; Mullings EL; Munafò MR; Nutt DJ; Melichar JK; Donaldson LF
J Psychopharmacol; 2013 Mar; 27(3):265-75. PubMed ID: 23364815
[TBL] [Abstract][Full Text] [Related]
13. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Poser W; Ehrenreich H
Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
[No Abstract] [Full Text] [Related]
14. Caring for patients with opioid use disorder in the hospital.
Donroe JH; Holt SR; Tetrault JM
CMAJ; 2016 Dec; 188(17-18):1232-1239. PubMed ID: 27647616
[No Abstract] [Full Text] [Related]
15. Methylnaltrexone (Relistor) for opioid induced constipation.
Med Lett Drugs Ther; 2008 Aug; 50(1292):63-4. PubMed ID: 18688204
[No Abstract] [Full Text] [Related]
16. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
[TBL] [Abstract][Full Text] [Related]
17. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
[TBL] [Abstract][Full Text] [Related]
18. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.
Cruciani RA; Lussier D; Miller-Saultz D; Arbuck DM
J Pain Symptom Manage; 2003 Jun; 25(6):491-4. PubMed ID: 12782427
[No Abstract] [Full Text] [Related]
19. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for Substance Use Disorders.
Klein JW
Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
